Table 1. Clinical and treatment characteristics.
| Parameters | No. of patients (n=57) |
|---|---|
|
Age (years) | |
| Range | 36–95 |
| Median | 67 |
|
Gender | |
| Male | 36 |
| Female | 21 |
|
Karnofsky performance status (KPS) | |
| Range | 70–90 |
| Median | 80 |
|
Baseline haemoglobin | |
| Median, g dl−1 (range) | 12.6 (8.7–17) |
|
Post-induction haemoglobin | |
| Median, g dl−1 (range) | 11.7 (8.3–15.9) |
|
Site | |
| Upper oesophagus | 16 |
| Middle oesophagus | 23 |
| Lower oesophagus | 15 |
| GE | 3 |
|
Tumour length on initial EUS (cm) | |
| Range | 0.3–15 |
| Median | 5.0 |
|
Histological differentiation | |
| Poorly differentiated | 25 |
| Moderately differentiated | 24 |
| Well differentiated | 2 |
| Unknown | 6 |
|
TNM staging | |
| Tx | 3 |
| T1 | 2 |
| T2 | 9 |
| T3 | 41 |
| T4 | 2 |
| N0 | 11 |
| N1 | 45 |
| N2 | 1 |
|
Radiation therapy details | |
| 4500 cGy | 1 |
| 5040–5200 cGy | 25 |
| 5600 cGy | 24 |
| 6000 cGy | 7 |
| Underwent surgery | 10 |
|
Induction chemotherapy | |
| Platinum and irinotecan regimen | 35 |
| Platinum and taxane regimen | 14 |
| Fluorouracil-containing regimen | 3 |
| Did not receive chemotherapy | 5 |
|
Concurrent chemotherapy | |
| Platinum and irinotecan regimen | 29 |
| Platinum and taxane regimen | 15 |
| Fluorouracil-containing regimen | 8 |
| Other | 5 |
Abbreviations: EUS=endoscopic ultrasound; TNM=extent of primary tumour-lymph nodes-metastases based on 2002 AJCC classification.